Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
ANESTHESIOLOGY / CLINICAL RESEARCH
Remimazolam tosilate in patients undergoing upper gastrointestinal endoscopy: a multicenter, randomized, dose-exploration, positive-controlled, parallel-group, phase II trial
1
Department of Anesthesiology, Chinese Academy of Medical College and Peking Union Medical College Hospital, Beijing, China
2
Clinical Pharmacology Research Center, Chinese Academy of Medical College and Peking Union Medical College Hospital
3
Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
4
Department of Anesthesiology, Beijing TongRen Hospital, Capital Medical University, Beijing, China
5
Department of Anesthesiology, Nanjing First Hospital, Nanjing, China
6
Department of Anesthesiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
7
Department of Anesthesiology, Yijishan Hospital of Wannan Medical College, Wuhu, China
8
Department of Anesthesiology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou, China
9
Department of Anesthesiology, SIR RUN RUN SHAW Hospital, Zhejiang University School of Medicine, Hangzhou, China
Submission date: 2020-04-07
Final revision date: 2020-06-10
Acceptance date: 2020-06-10
Online publication date: 2020-07-13
Publication date: 2026-02-28
Corresponding author
Yu-Guang Huang
Department of Anesthesiology Chinese Academy of Medical College and Peking Union Medical College Hospital No. 1 Shuaifu Garden Dongcheng District Beijing 100730 China Phone: +86 13601121351
Department of Anesthesiology Chinese Academy of Medical College and Peking Union Medical College Hospital No. 1 Shuaifu Garden Dongcheng District Beijing 100730 China Phone: +86 13601121351
Arch Med Sci 2026;22(1):282-289
KEYWORDS
TOPICS
ABSTRACT
Introduction:
To assess both the safety and efficacy of different doses of remimazolam tosilate (HR7056) in maintaining suitable sedation during upper gastrointestinal endoscopy and the reversibility of HR7056’s sedative effects with flumazenil.
Material and methods:
A total of 156 patients were enrolled and randomly received propofol (group A), 1 of 3 induction doses of HR7056 (8.0 mg (group B), 7.0 mg (group C), 5.0 mg (group D)), or 5.0 mg of HR7056 plus flumazenil (group E). The primary efficacy endpoint was the successful sedation rate. Adverse events (AEs) were recorded to evaluate safety.
Results:
Baseline characteristics of patients were well balanced between five treatment groups. For the dose-exploration part, there were no significant difference in successful sedation rate, rates of hypotension and respiratory depression between the four treatment groups. The sedative recovery time in group A was significantly higher than that in group B. The rate of hypoxemia and pain on injection in group A were both significantly higher than those in groups B, C and D. For the flumazenil reversal part, there was no significant difference in the sedative recovery time between group D and group E. The rates of AEs in groups A, B, C, D, E were 40.00%, 29.03%, 16.13%, 6.45%, 6.67%, respectively. There were no serious AEs.
Conclusions:
HR7056 was comparable to propofol in safety and efficacy in maintaining sedation during upper gastrointestinal endoscopy. HR7056 5.0/2.5 mg-dose (initial dose 5.0 mg, combined with supplemental doses of 2.5 mg) was capable of inducing rapid sedation without the need for flumazenil reversal.
To assess both the safety and efficacy of different doses of remimazolam tosilate (HR7056) in maintaining suitable sedation during upper gastrointestinal endoscopy and the reversibility of HR7056’s sedative effects with flumazenil.
Material and methods:
A total of 156 patients were enrolled and randomly received propofol (group A), 1 of 3 induction doses of HR7056 (8.0 mg (group B), 7.0 mg (group C), 5.0 mg (group D)), or 5.0 mg of HR7056 plus flumazenil (group E). The primary efficacy endpoint was the successful sedation rate. Adverse events (AEs) were recorded to evaluate safety.
Results:
Baseline characteristics of patients were well balanced between five treatment groups. For the dose-exploration part, there were no significant difference in successful sedation rate, rates of hypotension and respiratory depression between the four treatment groups. The sedative recovery time in group A was significantly higher than that in group B. The rate of hypoxemia and pain on injection in group A were both significantly higher than those in groups B, C and D. For the flumazenil reversal part, there was no significant difference in the sedative recovery time between group D and group E. The rates of AEs in groups A, B, C, D, E were 40.00%, 29.03%, 16.13%, 6.45%, 6.67%, respectively. There were no serious AEs.
Conclusions:
HR7056 was comparable to propofol in safety and efficacy in maintaining sedation during upper gastrointestinal endoscopy. HR7056 5.0/2.5 mg-dose (initial dose 5.0 mg, combined with supplemental doses of 2.5 mg) was capable of inducing rapid sedation without the need for flumazenil reversal.
REFERENCES (23)
1.
Ye L, Xiao X, Zhu L. The comparison of etomidate and propofol anesthesia in patients undergoing gastrointestinal endoscopy: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech 2017; 27: 1-7.
2.
Travis AC, Pievsky D, Saltzman JR. Endoscopy in the elderly. Am J Gastroenterol 2012; 107: 1495-501.
3.
Cao H, Wang B, Zhang Z, Zhang H, Qu R. Distribution trends of gastric polyps: an endoscopy database analysis of 24 121 northern Chinese patients. J Gastroenterol Hepatol 2012; 27: 1175-80.
4.
Meng QT, Cao C, Liu HM, et al. Safety and efficacy of etomidate and propofol anesthesia in elderly patients undergoing gastroscopy: a double-blind randomized clinical study. Exp Ther Med 2016; 12: 1515-24.
5.
Zhang R, Lu Q, Wu Y. The comparison of midazolam and propofol in gastrointestinal endoscopy: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech 2018; 28: 153-8.
6.
Wadhwa V, Issa D, Garg S, et al. Similar risk of cardiopulmonary adverse events between propofol and traditional anesthesia for gastrointestinal endoscopy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 194-206.
7.
Cohen LB, DeLegge MH, Aisenberg J, et al. AGA Institute review of endoscopic sedation. Gastroenterology 2007; 133: 675-701.
8.
Garewal D, Powell S, Milan SJ, Nordmeyer J, Waikar P. Sedative techniques for endoscopic retrograde cholangiopancreatography. Cochrane Database Syst Rev 2012; 6: CD007274.
9.
Borkett KM, Riff DS, Schwartz HI, et al. A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesthesia Analgesia 2015; 120: 771-80.
10.
Pastis NJ, Yarmus LB, Schippers F, et al. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest 2019; 155: 137-46.
11.
Bartkowska-Śniatkowska A, Wiczling P, Juzwa-Sobieraj M, et al. The pharmacokinetics of midazolam and 1-OH-midazolam during oral premedication in paediatric patients. J Med Sci 2016; 85: 73-82.
12.
Pambianco DJ, Borkett KM, Riff DS, et al. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy. Gastrointest Endosc 2016; 83: 984-92.
13.
Zhou Y, Hu P, Huang Y, et al. Population pharmacokinetic/pharmacodynamic model-guided dosing optimization of a novel sedative HR7056 in Chinese healthy subjects. Front Pharmacol 2018; 9: 1316.
14.
Rogers WK, McDowell TS. Remimazolam, a short-acting GABA (A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures. IDrugs 2010; 13: 929-37.
15.
Upton RN, Somogyi A, Martinez A, Colvill J, Grant C. Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep. Br J Anaesth 2010; 105: 798-809.
16.
Kerker A, Hardt C, Schlief HE, Dumoulin FL. Combined sedation with midazolam/propofol for gastrointestinal endoscopy in elderly patients. BMC Gastroenterol 2010; 10: 11.
17.
Tsai HC, Lin YC, Ko CL, et al. Propofol versus midazolam for upper gastrointestinal endoscopy in cirrhotic patients: a meta-analysis of randomized controlled trials. PLoS One 2015; 10: e0117585.
18.
Zhou Y, Hu P, Jiang J. Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry. J Pharm Biomed Analysis 2017; 137: 78-83.
19.
Bansal S, Singhal S. Remimazolam (CNS 7056): an emerging sedative and general anaesthetic. J Clin Diagn Res 2018; 12: UE01-3.
20.
Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc 2018; 88: 427-37.
21.
Larouche CB, Beaufrère H, Mosley C, Nemeth NM, Dutton C. Evaluation of the effects of midazolam and flumazenil in the ball python (Python regius). J Zoo Wildlife Med 2019; 50: 579-88.
22.
Seelhammer TG, DeGraff EM, Behrens TJ, et al. The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes. Brazil J Anesthesiol 2018; 68: 329-35.
23.
Worthington MT, Antonik LJ, Goldwater DR, et al. A phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesthesia Analgesia 2013; 117: 1093-100.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
